Imsidolimab is a Monoclonal Antibody owned by AnaptysBio, and is involved in 7 clinical trials, of which 4 were completed, and 3 are ongoing.

ANB019 is an anti-interleukin-36 receptor (IL-36R) antibody. It acts by neutralizing the actions of IL-36R. Incidence of  pustular psoriasis is correlated with mutations in the IL-36R signaling pathway. Upregulation of IL-36 function leads to the uncontrolled inflammatory episodes and incidence of pustular psoriasis. The drug candidate by acting as an antagonist of IL-36R signalling, forms as beneficial treatment for pustular psoriasis.

The revenue for Imsidolimab is expected to reach a total of $190m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Imsidolimab NPV Report.

Imsidolimab is originated and owned by AnaptysBio.

Imsidolimab Overview

Imsidolimab (ANB-019) is under development for the treatment of generalized pustular psoriasis (GPP). It is administered through the subcutaneous and intravenous route. The drug candidate acts by targeting the interleukin-36 receptor (IL-36R). It is developed based upon somatic hypermutation (SHM) Platform.

It was under development for the treatment of palmo-plantar pustular psoriasis (PPP), hidradenitis suppurativa, palmoplantar pustulosis (PPP),acne vulgaris, Ichthyosis and EGFRi/MEKi therapy mediated acneiformrash.

AnaptysBio Overview

AnaptysBio is a clinical-stage biotechnology company that focuses on the development of antibody candidates for the treatment of atopic dermatitis, ovarian cancer, lung cancer, asthma, psoriasis, inflammation, and other autoimmune indications. The company develops its product candidates through its proprietary antibody discovery technology platform that is based on somatic hypermutation (SHM). The company has various product candidates under development for the treatment of moderate-to-severe adult atopic dermatitis, asthma, generalized pustular psoriasis and palmo-plantar pustular psoriasis, and human autoimmune diseases. The company has partnership with GlaxoSmithKline and Bristol-Myers Squibb to develop its product candidates. AnaptysBio is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$63.2 million for the fiscal year ended December 2021 (FY2021), a decrease of 15.8% over FY2020. The operating loss of the company was US$56.8 million in FY2021, compared to an operating loss of US$23.9 million in FY2020. The net loss of the company was US$57.8 million in FY2021, compared to a net loss of US$19.9 million in FY2020. The company reported revenues of US$1.3 million for the third quarter ended September 2022, an increase of 6.3% over the previous quarter.

Quick View – Imsidolimab

Report Segments
  • Innovator
Drug Name
  • Imsidolimab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Dermatology
  • Genetic Disorders
  • Immunology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.